Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis

Journal of Clinical Oncology

Volumn 27, Issue 17, 2009, Pages 2793-2799

  Tomida, Shuta ^b   Takeuchi, Toshiyuki ^b   Shimada, Yukako ^b   Arima, Chinatsu ^b   Matsuo, Keitaro ^b   Mitsudomi, Tetsuya ^b   Yatabe, Yasushi ^b   Takahashi, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR PROBE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRAINING; VALIDATION STUDY; ADENOCARCINOMA; CANCER STAGING; COHORT ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN GENOME; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; RECURRENT DISEASE; RISK;

BIOLOGICAL MARKER;

ADENOCARCINOMA; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK; VALIDATION STUDIES AS TOPIC;

EID: 67649965344     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.7053     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. McCracken M, Olsen M, Chen MS Jr, et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57:190-205, 2007
3. Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer 7:778-790, 2007
4. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355:479-485, 2000
5. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer 7:545-553, 2007
6. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98:13784-13789, 2001
7. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790-13795, 2001
8. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
9. Tomida S, Koshikawa K, Yatabe Y, et al: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 23:5360-5370, 2004
10. Jones MH, Virtanen C, Honjoh D, et al: Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363:775-781, 2004
11. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006
12. Shedden K, Taylor JM, Enkemann SA, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 14:822-827, 2008
13. Takeuchi T, Tomida S, Yatabe Y, et al: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 24:1679-1688, 2006
14. Yanagisawa K, Tomida S, Shimada Y, et al: A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 99:858-867, 2007
15. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998
16. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
17. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436:518-524, 2005
18. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503-1521, 2005
19. Lau SK, Boutros PC, Pintilie M, et al: Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25:5562-5569, 2007
20. Chen HY, Yu SL, Chen CH, et al: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11-20, 2007
21. Lu Y, Lemon W, Liu PY, et al: A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3:e467, 2006
22. Bianchi F, Nuciforo P, Vecchi M, et al: Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 117:3436-3444, 2007
23. Larsen JE, Pavey SJ, Passmore LH, et al: Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13:2946-2954, 2007
24. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
25. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
26. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
27. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 24:365s, 2006 (suppl; abstr 7007)
28. Wakelee H, Dubey S, Gandara D: Optimal adjuvant therapy for non-small cell lung cancer-how to handle stage I disease. Oncologist 12:331-337, 2007